First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.

RADICAVA™ (edaravone) Indicated for All Adult Patients Diagnosed with ALS JERSEY CITY, N.J., Aug. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therap... Biopharmaceuticals, Neurology, Product Launch Mitsubishi Tanabe Pharma, RADICAVA, edaravone, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news